Clinical Trial Update: Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial is testing dual-target CAR-NK cell therapy directed against MSLN, EGFR, or HER2 in patients with advanced non-small cell lung c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CAR-NK cell therapy targeting MSLN, EGFR, or HER2

Snippet

Sponsor: Beijing Biotech | Conditions: Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC | Phase 1, Phase 2 | Status: RECRUITING